- Business
- Acarix AB (publ) (ACARIX.ST) develops and commercializes the CADScor System, a non-invasive, AI-based acoustic diagnostic aid for rapid point-of-care rule-out of significant coronary artery disease in symptomatic patients; the system employs ultra-sensitive phonocardiography to detect turbulent coronary blood flow, generating a patient-specific CAD-score (0-99) in under eight minutes using advanced algorithms that incorporate age, gender, and risk factors; it requires disposable patches for single-patient use and integrates with electronic health records via QR code scanning. Founded in 2009 and headquartered in Malmö, Sweden, the company operates primarily in the U.S. market through its subsidiary Acarix USA Inc., with additional presence in the Nordics, United Kingdom, Germany, MENA region, and select international markets via distributors; it targets cardiology practices, emergency departments, outpatient clinics, Veterans Affairs healthcare, concierge medicine, and wellness providers. In recent developments, Acarix enters 2025 with a favorable U.S. CMS ruling for standalone fixed reimbursement of the CADScor System under APC 5733 in outpatient settings, secures multi-unit system orders from national concierge practices and cardiology groups, achieves first commercial sales in MENA with 17 systems sold in Q3 2025, reports 137% Q3 revenue growth to SEK 2.35 million driven by 95% increase in system deliveries and 80% patch sales growth, expands U.S. reimbursement with three major payors removing experimental labels and a second fixed-rate agreement at USD 300 per test including HealthChoice in Oklahoma, advances the Heart Failure Seismo algorithm accepted for American Heart Association presentation, lists shares on OTCQB (ACIXF), adopts a growth-focused usage-based consignment model boosting U.S. placements by 28% year-to-date, and strengthens leadership with key hires in U.S. sales, finance, and reimbursement.